Coral Laboratories Ltd.
BSE: CORALAB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Coral Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Coral India Finance and Housing Limited operates as a diversified entity with core interests in real estate development and financial services. The company focuses on residential and commercial construction projects alongside proprietary investment and credit activities.
Geography mix
- NaN%
- NaN%
Business Model
The company generates revenue through the development and sale of real estate assets and by managing proprietary investments and credit facilities. It maintains a conservative financial profile, characterised by a debt-free balance sheet and a history of consistent dividend distributions.
- Debt Status:Debt-free
Management Commentary
Management maintains a conservative approach to capital allocation, prioritising niche redevelopment projects and balance sheet stability. The firm continues to leverage its historical market presence to sustain its financial and operational objectives.
Growth Outlook
Growth is expected to be driven by the company's focus on niche redevelopment projects within the Mumbai and Thane regions. The firm remains committed to its conservative strategy while exploring opportunities within its existing business segments.
Key Risks
- Market Concentration. The company's real estate operations are highly concentrated in the Mumbai and Thane regions, making it vulnerable to local market fluctuations.
- Regulatory Risk. Changes in real estate regulations and urban development policies could significantly impact project timelines and profitability.
- Interest Rate Sensitivity. As a provider of credit facilities, the company is exposed to interest rate volatility which may affect the demand for its financial services.
- Execution Risk. The reliance on niche redevelopment projects involves complex legal and construction challenges that could lead to project delays.
Start your research today
Unlock AI insights, financials, peers and live data on Coral Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹86 Cr
TTM · standalone
NET PROFIT
₹16 Cr
TTM · standalone
EPS
₹45.86
TTM · standalone
RETURN ON EQUITY
8.1%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
11.3%
TTM · standalone
P/E
13.1x
Q4 FY26 · standalone
EV/EBITDA
5.8x
Q4 FY26 · standalone
EBITDA MARGIN
29.2%
TTM · standalone
NET PROFIT MARGIN
19.7%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Coral Laboratories Ltd.CORALAB | ₹230 Cr | 14.02 | 9.27 | -25.3% | 29.2% | 8.1% | 11.3% | +44.2% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Coral Laboratories Ltd.
BSE: CORALAB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Coral Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Coral India Finance and Housing Limited operates as a diversified entity with core interests in real estate development and financial services. The company focuses on residential and commercial construction projects alongside proprietary investment and credit activities.
Geography mix
- NaN%
- NaN%
Business Model
The company generates revenue through the development and sale of real estate assets and by managing proprietary investments and credit facilities. It maintains a conservative financial profile, characterised by a debt-free balance sheet and a history of consistent dividend distributions.
- Debt Status:Debt-free
Management Commentary
Management maintains a conservative approach to capital allocation, prioritising niche redevelopment projects and balance sheet stability. The firm continues to leverage its historical market presence to sustain its financial and operational objectives.
Growth Outlook
Growth is expected to be driven by the company's focus on niche redevelopment projects within the Mumbai and Thane regions. The firm remains committed to its conservative strategy while exploring opportunities within its existing business segments.
Key Risks
- Market Concentration. The company's real estate operations are highly concentrated in the Mumbai and Thane regions, making it vulnerable to local market fluctuations.
- Regulatory Risk. Changes in real estate regulations and urban development policies could significantly impact project timelines and profitability.
- Interest Rate Sensitivity. As a provider of credit facilities, the company is exposed to interest rate volatility which may affect the demand for its financial services.
- Execution Risk. The reliance on niche redevelopment projects involves complex legal and construction challenges that could lead to project delays.
Start your research today
Unlock AI insights, financials, peers and live data on Coral Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹86 Cr
TTM · standalone
NET PROFIT
₹16 Cr
TTM · standalone
EPS
₹45.86
TTM · standalone
RETURN ON EQUITY
8.1%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
11.3%
TTM · standalone
P/E
13.1x
Q4 FY26 · standalone
EV/EBITDA
5.8x
Q4 FY26 · standalone
EBITDA MARGIN
29.2%
TTM · standalone
NET PROFIT MARGIN
19.7%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26